Develops novel immune therapeutics for the prevention, treatment, and mitigation of infections. Focuses on bacterial, fungal, and parasitic infections. Now — the numbers.

We do not hold enough financial data on this company to point to a strength.

We do not hold enough financial data on this company to name a risk — which is itself a reason for caution.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

One-line summary: few numbers, an untested story. Keep watching.

Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown, the price history.